VB-MAPP Alternatives: 6 ABA Assessments Compared (and How to Choose)
The VB-MAPP is one of the most widely used assessments in ABA, but it isn’t the only option — and it isn’t
EarliPoint Health Launches Project ALIGN to Advance Objective Measurement and Outcomes in Autism Care
Learn More →The VB-MAPP is one of the most widely used assessments in ABA, but it isn’t the only option — and it isn’t
The last day of school felt like exhaling. No schedule, no rushed mornings, no homework pile by the door. But now it’s
As autism prevalence reaches 1 in 31 children and diagnostic wait times for autism evaluations often extend four months or longer at
The Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) is a norm-referenced measure of adaptive behavior — the everyday practical skills a person
The Vineland-3 is one of the most widely used adaptive behavior measure in autism and ABA, and for good reason. It captures
For providers using the EarliPoint System as part of the autism evaluation process, one of the recurring operational questions is how to
The operational picture for ABA practices has shifted meaningfully over the last 18 to 24 months. Some of the change is driven
The autism diagnostic environment has matured, changing how pediatric practices think about referrals. Where once there were one or two specialty centers
Spotting the signs of autism is only the first step. Once a parent decides to pursue a formal evaluation, the next question
If your child’s pediatrician hands you a questionnaire and says the results “raise some concerns,” what that really means is that your
The pace of clinical technology development in healthcare has accelerated. For practice owners and clinical directors evaluating new tools, the volume of
A difference of a few years may not sound like much, but in autism spectrum disorder, earlier identification can open critical windows
Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.
Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.
Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.